Icotinib at Different Doses in Second-line Treatment for Non-small Cell Lung Cancer Patients With Wild Type EGFR
Status:
Unknown status
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate the safety and efficacy of icotinib at routine dose and
higher dose as second-line treatment in non-small cell lung cancer patients with epidermal
growth factor receptor of wild type.
Phase:
Phase 2
Details
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital